Emendo Biotherapeutics
Developing genetic medicines and cell therapies for severe diseases using proprietary CRISPR OMNI technology.
About
Emendo Biotherapeutics is a genome editing company focused on creating novel genetic medicines and cell therapies for patients suffering from severe diseases. Their approach leverages proprietary protein engineering and selection platforms to generate highly specific and potent CRISPR OMNI nucleases, aiming to overcome limitations of existing gene editing tools. Teams look it up for Healthcare, Genome Editing, CRISPR.
Frequently asked
What does Emendo Biotherapeutics do?
Emendo Biotherapeutics is a Healthcare company that offers Platform. Teams look it up for Genome Editing, CRISPR, Biotech. It is based in Tel Aviv, Israel and was founded in 2015. Public records show about 41 people and $61M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Emendo Biotherapeutics raised?
Emendo Biotherapeutics has raised a total of $61M in funding. The most recent round on record is Series B.
Where is Emendo Biotherapeutics headquartered?
Emendo Biotherapeutics is headquartered in Tel Aviv, Israel.
When was Emendo Biotherapeutics founded?
Emendo Biotherapeutics was founded in 2015.
What industry does Emendo Biotherapeutics operate in?
Emendo Biotherapeutics operates in Healthcare, Genome Editing, CRISPR, Biotech, MedTech.
How many employees does Emendo Biotherapeutics have?
Emendo Biotherapeutics has approximately 41 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.